NovoCure Limited (NASDAQ:NVCR) COO Michael J. Ambrogi sold 24,327 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $22.01, for a total value of $535,437.27. Following the sale, the chief operating officer now owns 49,514 shares in the company, valued at approximately $1,089,803.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NovoCure Limited (NASDAQ NVCR) opened at $17.05 on Tuesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.30 and a current ratio of 5.90. NovoCure Limited has a fifty-two week low of $6.00 and a fifty-two week high of $22.30.
NovoCure Limited (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.07. The business had revenue of $50.10 million during the quarter, compared to the consensus estimate of $43.45 million. NovoCure Limited had a negative return on equity of 57.68% and a negative net margin of 47.45%. NovoCure Limited’s quarterly revenue was up 130.9% on a year-over-year basis. During the same period last year, the company earned ($0.39) earnings per share. equities analysts predict that NovoCure Limited will post -0.63 earnings per share for the current fiscal year.
WARNING: “Michael J. Ambrogi Sells 24,327 Shares of NovoCure Limited (NASDAQ:NVCR) Stock” was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.truebluetribune.com/2017/11/14/insider-selling-novocure-limited-nvcr-coo-sells-535437-27-in-stock.html.
A number of hedge funds have recently bought and sold shares of NVCR. Goldman Sachs Group Inc. grew its stake in NovoCure Limited by 6,617.7% in the second quarter. Goldman Sachs Group Inc. now owns 4,988,007 shares of the medical equipment provider’s stock valued at $86,293,000 after purchasing an additional 4,913,755 shares in the last quarter. FMR LLC grew its stake in NovoCure Limited by 50.4% in the second quarter. FMR LLC now owns 6,888,120 shares of the medical equipment provider’s stock valued at $119,165,000 after purchasing an additional 2,309,559 shares in the last quarter. Vanguard Group Inc. grew its stake in NovoCure Limited by 40.5% in the second quarter. Vanguard Group Inc. now owns 4,283,862 shares of the medical equipment provider’s stock valued at $74,111,000 after purchasing an additional 1,235,922 shares in the last quarter. Frontier Capital Management Co. LLC bought a new position in NovoCure Limited in the second quarter valued at approximately $14,308,000. Finally, PointState Capital LP bought a new position in NovoCure Limited in the second quarter valued at approximately $5,744,000. Hedge funds and other institutional investors own 36.21% of the company’s stock.
Several equities analysts recently issued reports on NVCR shares. Zacks Investment Research cut NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Wedbush reissued an “outperform” rating and issued a $25.00 target price (down previously from $29.00) on shares of NovoCure Limited in a research note on Friday, October 27th. BidaskClub raised NovoCure Limited from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 31st. Mizuho assumed coverage on NovoCure Limited in a research note on Wednesday, September 6th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $19.00 target price (up previously from $18.00) on shares of NovoCure Limited in a research note on Monday, July 17th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $21.00.
About NovoCure Limited
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.